Quoin Pharmaceuticals (QNRX) Receivables (2017 - 2020)

Quoin Pharmaceuticals (QNRX) posted Receivables of $176000.0 for Q4 2020, down 59.63% sequentially from $436000.0 in Q4 2018.

Quoin Pharmaceuticals (QNRX) Receivables (2017 - 2020) Analysis & Trends

Quoin Pharmaceuticals has reported Receivables for 3 years, with the latest figure at $176000.0 in Q4 2020.

Quarterly Receivables changed N/A year-over-year to $176000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $176000.0 (changed N/A YoY) and the FY2020 annual result came in at $176000.0, down 35.29% from the prior year.
Receivables slipped to $176000.0 in Q4 2020 per QNRX's latest filing, from $436000.0 in the prior quarter.
Over five years, Receivables peaked at $436000.0 in Q4 2018 and troughed at $176000.0 in Q4 2020.
A 3-year average of $288333.3 and a median of $253000.0 in 2017 frame the typical range for Receivables.
The widest YoY moves for Receivables: up 72.33% in 2018, down 72.33% in 2018.
Over 3 years, Receivables stood at $253000.0 in 2017, then soared by 72.33% to $436000.0 in 2018, then tumbled by 59.63% to $176000.0 in 2020.
According to Business Quant data, Receivables over the past three periods registered $176000.0, $436000.0, and $253000.0 for Q4 2020, Q4 2018, and Q4 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	Quoin Pharmaceuticals	491,038.58	491,038.58	-	-

Download Data